132 related articles for article (PubMed ID: 36228576)
21. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.
Grossfeld GD; Small EJ; Carroll PR
Urology; 1998 Jan; 51(1):137-44. PubMed ID: 9457309
[TBL] [Abstract][Full Text] [Related]
22. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
23. Visual field and orbital computed tomography correlation in dysthyroid optic neuropathy due to thyroid eye disease.
Starks VS; Reinshagen KL; Lee NG; Freitag SK
Orbit; 2020 Apr; 39(2):77-83. PubMed ID: 31057005
[No Abstract] [Full Text] [Related]
24. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.
Uehara S; Yuasa T; Fujii Y; Yano A; Yamamoto S; Masuda H; Fukui I; Yonese J
BMC Res Notes; 2015 Aug; 8():335. PubMed ID: 26242866
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic Radiotherapy for Lesions Detected via
Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
[TBL] [Abstract][Full Text] [Related]
26. Predominant Contribution of Superior Rectus-Levator Complex Enlargement to Optic Neuropathy and Inferior Visual Field Defects in Thyroid Eye Disease.
Oropesa S; Dunbar KE; Godfrey KJ; Callahan AB; Campbell AA; Kazim M
Ophthalmic Plast Reconstr Surg; 2019; 35(3):262-265. PubMed ID: 30124604
[TBL] [Abstract][Full Text] [Related]
27. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
[TBL] [Abstract][Full Text] [Related]
28. Computed tomography imaging-based normative orbital measurement in Indian population.
Gupta V; Prabhakar A; Yadav M; Khandelwal N
Indian J Ophthalmol; 2019 May; 67(5):659-663. PubMed ID: 31007233
[TBL] [Abstract][Full Text] [Related]
29. A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.
McKay RR; Zurita AJ; Werner L; Bruce JY; Carducci MA; Stein MN; Heath EI; Hussain A; Tran HT; Sweeney CJ; Ross RW; Kantoff PW; Slovin SF; Taplin ME
J Clin Oncol; 2016 Jun; 34(16):1913-20. PubMed ID: 27044933
[TBL] [Abstract][Full Text] [Related]
30. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
31. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
32. Flare on [
Malaspina S; Ettala O; Tolvanen T; Rajander J; Eskola O; Boström PJ; Kemppainen J
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):613-621. PubMed ID: 36161511
[TBL] [Abstract][Full Text] [Related]
33. Agonists of luteinizing hormone-releasing hormone in prostate cancer.
Rick FG; Block NL; Schally AV
Expert Opin Pharmacother; 2013 Nov; 14(16):2237-47. PubMed ID: 23984804
[TBL] [Abstract][Full Text] [Related]
34. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy.
Morote J; Comas I; Planas J; Maldonado X; Celma A; Placer J; Ferrer R; Carles J; Regis L
Clin Genitourin Cancer; 2018 Apr; 16(2):e491-e496. PubMed ID: 29198640
[TBL] [Abstract][Full Text] [Related]
35. Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial.
Hölscher T; Baumann M; Kotzerke J; Zöphel K; Paulsen F; Müller AC; Zips D; Koi L; Thomas C; Löck S; Krause M; Wirth M; Lohaus F
Eur Urol Oncol; 2022 Feb; 5(1):44-51. PubMed ID: 34785189
[TBL] [Abstract][Full Text] [Related]
36. Normative measurements of Korean orbital structures revealed by computerized tomography.
Lee JS; Lim DW; Lee SH; Oum BS; Kim HJ; Lee HJ
Acta Ophthalmol Scand; 2001 Apr; 79(2):197-200. PubMed ID: 11284763
[TBL] [Abstract][Full Text] [Related]
37. MRI measurements of normal extraocular muscles and other orbital structures.
Tian S; Nishida Y; Isberg B; Lennerstrand G
Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):393-404. PubMed ID: 10901470
[TBL] [Abstract][Full Text] [Related]
38. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen and androgen deprivation therapy.
Ruckle HC; Oesterling JE
World J Urol; 1993; 11(4):227-32. PubMed ID: 7508789
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
